


Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1 (currently amended): A process ~~Process~~ for the preparation of a N-(N'-substituted glycyI)-2-cyanopyrrolidine comprising at least

(a) reacting, in the presence of dimethylformamide, a compound of formula (V)



(V)

wherein, independently of each other, X1 and X3 are halogen; X2 is halogen, OH,

O-C(=O)-CH₂X₃, -O-SO₂-(C₁₋₈)alkyl or -O-SO₂-(aryl),


with L-prolinamide, followed by

(b) reacting the resultant compound without isolation with a dehydration agent, optionally followed by

(c) reacting, in the presence of a base, the resultant compound without isolation with an appropriate amine and

(d) recovering the resultant compound in free form or in acid addition salt form.

Claim 2 (original): A process according to claim 1 wherein the N-(N'-substituted glycyI)-2-cyanopyrrolidine is a compound of formula (I)



(I)

wherein R is

a) R₁R_{1a}N(CH₂)_m - wherein

R₁ is a pyridinyl or pyrimidinyl moiety optionally mono- or independently disubstituted with (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen, trifluoromethyl, cyano or nitro; or phenyl optionally mono- or independently disubstituted with (C₁₋₄)alkyl, (C₁₋₄)alkoxy or halogen;

R_{1a} is hydrogen or (C₁₋₈)alkyl; and

m is 2 or 3;

b) (C₃₋₁₂)cycloalkyl optionally monosubstituted in the 1-position with (C₁₋₃)hydroxyalkyl;

c) R₂(CH₂)_n - wherein either

R₂ is phenyl optionally mono- or independently di- or independently trisubstituted with (C₁₋₄)alkyl, (C₁₋₄)alkoxy, halogen or phenylthio optionally monosubstituted in the phenyl ring with hydroxymethyl; or is (C₁₋₈)alkyl; a [3.1.1]bicyclic carbocyclic moiety optionally mono- or plurisubstituted with (C₁₋₈)alkyl; a pyridinyl or naphthyl moiety optionally mono- or independently disubstituted with (C₁₋₄)alkyl, (C₁₋₄)alkoxy or halogen; cyclohexenyl; or optionally substituted adamantyl; and

n is 1 to 3; or

R₂ is phenoxy optionally mono- or independently disubstituted with (C₁₋₄)alkyl, (C₁₋₄)alkoxy or halogen; and

n is 2 or 3;

d) (R₃)₂CH(CH₂)₂ - wherein each R₃ independently is phenyl optionally mono- or independently disubstituted with (C₁₋₄)alkyl, (C₁₋₄)alkoxy or halogen;

e) R₄(CH₂)_p - wherein R₄ is 2-oxopyrrolidinyl or (C₂₋₄)alkoxy and p is 2 to 4;

f) isopropyl optionally monosubstituted in 1-position with (C₁₋₃)hydroxyalkyl; or

g) R₅ wherein R₅ is: indanyl; a pyrrolidinyl or piperidinyl moiety optionally substituted with benzyl; a [2.2.1]- or [3.1.1]bicyclic carbocyclic moiety optionally mono- or multisubstituted with (C₁₋₈)alkyl; adamantyl; substituted adamantyl; or (C₁₋₈)alkyl optionally mono- or independently plurisubstituted with hydroxy, hydroxymethyl or phenyl optionally mono- or independently disubstituted with (C₁₋₄)alkyl, (C₁₋₄)alkoxy or halogen;

in free form or in acid addition salt form.

Claim 3 (currently amended): A process according to claim 1 ~~or 2~~ wherein the dehydration agent of step (b) is a (haloalkylene)dialkylammonium ~~halogenid~~ halide.

Claim 4 (currently amended): A process according to claim 1 ~~or 2~~ wherein the dehydration agent of step (b) is (chloromethylene)dimethylammonium chloride.


Claim 5 (original): A process according to claim 2 wherein the amine of step (c) is a compound of formula (VI)



wherein R is as defined for formula (I) in claim 2.

Claim 6 (original): A process according to claim 2 comprising

(a) reacting, in the presence of dimethylformamide, a compound of formula (V)



(V)

wherein X_1 is halogen; X_2 is halogen, OH, $\text{O}-\text{C}(=\text{O})-\text{CH}_2\text{X}$, $-\text{O}-\text{SO}_2-(\text{C}1-8)\text{alkyl}$ or $-\text{O}-\text{SO}_2-(\text{aryl})$, with L-prolinamide, followed by

(b) reacting the resultant compound without isolation with (chloromethylene)dimethylammonium chloride, followed by

(c) reacting, in the presence of a base, the resultant compound without isolation with a compound of formula (VI)



wherein R is as defined for formula (I) and

(d) recovering the resultant compound in free form or in acid addition salt form.

Claim 7 (original): A process according to claim 6 wherein R is $\text{R}_2(\text{CH}_2)_n$ and R_2 is substituted adamantyl; and n is 0, 1, 2 or 3.

Claim 8 (currently amended): A composition of N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine and N-(N'-substituted glycyI)-2(R)-cyanopyrrolidine, obtainable according to the process of claim 1 or 2, whereby 95% to 99.9 99.9% is N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine and 5% to 0.4 0.1% is N-(N'-substituted glycyI)-2(R)-cyanopyrrolidine, especially whereby 98% to 99.99 99.9% is N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine and 2% to 0.04 0.01% is N-(N'-substituted glycyI)-2(R)-cyanopyrrolidine.

Claim 9 (currently amended): A composition comprising a N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine and a N-(N'-substituted glycyI)-2(R)-cyanopyrrolidine, whereby 98% to 99.9 99.9% is N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine and 2% to 0.4% is N-(N'-substituted glycyI)-2(R)-cyanopyrrolidine, preferably whereby 98% to 99.99 99.9% is N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine and 2% to 0.01% is N-(N'-substituted glycyI)-2(R)-cyanopyrrolidine, most preferably whereby 99% to 99.99 99.9% is N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine and 1% to 0.04 0.01% is N-(N'-substituted glycyI)-2(R)-cyanopyrrolidine.

Claim 10 (currently amended): A composition of N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine and N-(N'-substituted glycyI)-2(R)-cyanopyrrolidine, obtainable according to the process of claim 1 or 2.

Claim 11 (currently amended): A pharmaceutical composition comprising,


- a) one or more pharmaceutically acceptable excipients, and
- b) at least one N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine obtainable according to the process of claim 1 ~~or~~ 2.

Claim 12 (currently amended): A pharmaceutical composition comprising,

- a) one or more pharmaceutically acceptable excipients, and
- b) at least one N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine, and
- c) between 0.00001% and 5% by weight of at least one (haloalkylene)dialkylammonium halogenid halide.

Claim 13 (currently amended): A composition according to claim 12, wherein the N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine is obtainable according to the process of claim 1 ~~or~~ 2.

Claim 14 (currently amended): A composition according to ~~any of~~ claim 8 ~~to~~ 13, whereby the N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine is a compound of the formula



wherein R' is hydroxy and R'' is hydrogen in free form or in acid addition salt form.

Claim 15 (new): A process according to claim 2 wherein the dehydration agent of step (b) is a (haloalkylene)dialkylammonium halide.

Claim 16 (new): A process according to claim 2 wherein the dehydration agent of step (b) is (chloromethylene)dimethylammonium chloride.


Claim 17 (new): A composition of N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine and N-(N'-substituted glycyI)-2(R)-cyanopyrrolidine, obtainable according to the process of claim 2, whereby 95% to 99.9% is N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine and 5% to 0.1% is N-(N'-substituted glycyI)-2(R)-cyanopyrrolidine, especially whereby 98% to 99.9% is N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine and 2% to 0.01% is N-(N'-substituted glycyI)-2(R)-cyanopyrrolidine.

Claim 18 (new): A composition of N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine and N-(N'-substituted glycyI)-2(R)-cyanopyrrolidine, obtainable according to the process of claim 2.

Claim 19 (new): A pharmaceutical composition comprising,
a) one or more pharmaceutically acceptable excipients, and
b) at least one N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine obtainable according to the process of claim 2.


Claim 20 (new): A composition according to claim 12, wherein the N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine is obtainable according to the process of claim 2.

Claim 21 (new): A composition according to claim 9, whereby the N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine is a compound of the formula




wherein R' is hydroxy and R'' is hydrogen in free form or in acid addition salt form.

Claim 22 (new): A composition according to claim 10, whereby the N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine is a compound of the formula




wherein R' is hydroxy and R'' is hydrogen in free form or in acid addition salt form.

Claim 23 (new): A composition according to claim 11, whereby the N-(N'-substituted glycyI)-2(S)-cyanopyrrolidine is a compound of the formula




wherein R' is hydroxy and R'' is hydrogen in free form or in acid addition salt form.

Claim 24 (new): A composition according to claim 12, whereby the N-(N'-substituted glycy)-2(S)-cyanopyrrolidine is a compound of the formula



wherein R' is hydroxy and R'' is hydrogen in free form or in acid addition salt form.

Claim 25 (new): A composition according to claim 13, whereby the N-(N'-substituted glycy)-2(S)-cyanopyrrolidine is a compound of the formula



wherein R' is hydroxy and R'' is hydrogen in free form or in acid addition salt form.